These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 371813)
21. Hyperthermia enhances the inhibition of tumor growth by 1-(2-tetrahydrofuryl)-5-fluorouracil/uracil (1:4) in tumors in mice and humans. Emi Y; Kohnoe S; Yoshida M; Takahashi I; Maehara Y; Sugimachi K Cancer; 1992 Sep; 70(5):1177-82. PubMed ID: 1515994 [TBL] [Abstract][Full Text] [Related]
22. Comparative effects of ftorafur and 5-fluorouracil on DNA synthesis in rat small intestine. Cohen AM Life Sci; 1975 Nov; 17(9):1363-7. PubMed ID: 1207401 [No Abstract] [Full Text] [Related]
23. Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Takechi T; Fujioka A; Matsushima E; Fukushima M Eur J Cancer; 2002 Jun; 38(9):1271-7. PubMed ID: 12044515 [TBL] [Abstract][Full Text] [Related]
24. Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil. Yasumoto M; Yamawaki I; Marunaka T; Hashimoto S J Med Chem; 1978 Aug; 21(8):738-41. PubMed ID: 357721 [TBL] [Abstract][Full Text] [Related]
25. The relationships between p53-dependent apoptosis, inhibition of proliferation, and 5-fluorouracil-induced histopathology in murine intestinal epithelia. Pritchard DM; Potten CS; Hickman JA Cancer Res; 1998 Dec; 58(23):5453-65. PubMed ID: 9850079 [TBL] [Abstract][Full Text] [Related]
26. [Immunotoxic effects of a new antineoplastic agent S-1 in mice--comparison with S-1, UFT and 5-FU]. Kouchi Y; Maeda Y; Morinaga H; Ohuchida A J Toxicol Sci; 1996 Nov; 21 Suppl 3():691-701. PubMed ID: 9021669 [TBL] [Abstract][Full Text] [Related]
27. Ftorafur: a self-limiting source of 5-fluorouracil? van Putten LM; Lelieveld P; Pantarotto C; Salmona M; Spreafico F Cancer Chemother Pharmacol; 1979; 3(1):61-6. PubMed ID: 119584 [No Abstract] [Full Text] [Related]
28. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Takechi T; Nakano K; Uchida J; Mita A; Toko K; Takeda S; Unemi N; Shirasaka T Cancer Chemother Pharmacol; 1997; 39(3):205-11. PubMed ID: 8996521 [TBL] [Abstract][Full Text] [Related]
29. [Human colorectal carcinoma is more sensitive to HCFU than 5-FU and tegafur in in vitro and in vivo drug sensitivity tests]. Kusumoto T; Maehara Y; Anai H; Kusumoto H; Miyamoto K; Fukuchi K; Sugimachi K Gan To Kagaku Ryoho; 1988 Feb; 15(2):257-61. PubMed ID: 3124767 [TBL] [Abstract][Full Text] [Related]
30. Serum concentrations of 5-FU, ftorafur, and a major serum metabolite following ftorafur chemotherapy. Hornbeck CL; Griffiths JC; Floyd RA; Ginther NC; Byfield JE; Sharp TR Cancer Treat Rep; 1981; 65(1-2):69-72. PubMed ID: 6784923 [TBL] [Abstract][Full Text] [Related]
31. Dipyridamole augments the antitumor effects of fluorinated pyrimidines. Sakaguchi Y; Kusumoto T; Kusumoto H; Maehara Y; Furusawa M; Sugimachi K Anticancer Res; 1992; 12(1):119-21. PubMed ID: 1567156 [TBL] [Abstract][Full Text] [Related]
32. Effect of thymidine on the toxicity and antitumor activity of ftorafur. Grossie VB; Loo TL Cancer Treat Rep; 1981; 65(11-12):1087-91. PubMed ID: 6794908 [TBL] [Abstract][Full Text] [Related]
33. [Effect of ftorafur and 5-fluorouracil on the chromosomes of human tumor cell cultures]. Sokova OI; Volgareva GM Genetika; 1979; 15(5):855-61. PubMed ID: 378768 [TBL] [Abstract][Full Text] [Related]
34. Effects of ftorafur and 5-fluorouracil on the canine sinoatrial node. Satoh H; Hashimoto K Jpn J Pharmacol; 1983 Apr; 33(2):357-62. PubMed ID: 6411954 [TBL] [Abstract][Full Text] [Related]
35. [Regulation of enzyme activities involved in pyrimidine synthesis and its application to cancer chemotherapy]. Shirasaka T; Fujii S Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):760-8. PubMed ID: 6424581 [TBL] [Abstract][Full Text] [Related]
36. Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. Ho DH; Covington W; Brown N; Lin SN; Pazdur R; Huo YY; Creaven PJ; Rustum YM; Meropol NJ; Lassere Y; Kuritani J; Hayakawa T Cancer Chemother Pharmacol; 2000; 46(5):351-6. PubMed ID: 11127938 [TBL] [Abstract][Full Text] [Related]
37. Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil. Toide H; Akiyoshi H; Minato Y; Okuda H; Fujii S Gan; 1977 Oct; 68(5):553-60. PubMed ID: 22472 [TBL] [Abstract][Full Text] [Related]
38. Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-k-fluorouracil into the R and S isomers and examination of the biological activities of the isomers. Yasumoto M; Moriyama A; Unemi N; Hashimoto S; Suzue T J Med Chem; 1977 Dec; 20(12):1592-4. PubMed ID: 338900 [TBL] [Abstract][Full Text] [Related]
39. In vitro biological evaluation of the R and S isomers of 1-(Tetrahydrofuran-2-yl)-5-fluorouracil. Horwitz JP; McCormick JJ; Philips KD; Maher VM; Otto JR; Kessel D; Zemlicka J Cancer Res; 1975 May; 35(5):1301-4. PubMed ID: 1168096 [TBL] [Abstract][Full Text] [Related]
40. Combination chemotherapy with cyclophosphamide and ftorafur against advanced L1210 murine leukemia. Grossie VB; Rosenblum MG; Loo TL Cancer Treat Rep; 1982 Aug; 66(8):1631-4. PubMed ID: 6809329 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]